Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
Two Melbourne-made COVID-19 vaccines demonstrated strong boosting capabilities against SARS-CoV-2 variants in a Phase 1 clinical trial. The vaccines focus the immune response on the receptor binding domain, potentially providing a more efficient approach to boost immunity.
Researchers discovered distinct mechanisms controlling different types of immune cells and found a way to selectively eliminate 'problematic' cells driving autoimmune disorders. This breakthrough offers precise targets for potential treatment strategies, potentially revolutionizing the way we treat skin conditions.
The Cumming Global Centre for Pandemic Therapeutics is offering global grants of up to $200,000 per annum for three years to develop novel therapeutics for pathogens of pandemic potential. Researchers are invited to submit expressions of interest for Round Two of the Foundation Grants program.
A University of Melbourne research team is developing an oral therapeutic to restore the activity of common antibiotics used to treat community-acquired bacterial pneumonia. The project aims to combat antibiotic-resistant bacteria and reduce healthcare costs, with potential applications in low- and middle-income countries.
Research finds that immune cells in older adults are similar to those in newborns and children, but less effective at recognizing infected cells. The study, published in Nature Immunology, suggests that tailored vaccines and therapies could be developed for different age groups based on the unique characteristics of killer T cells.
A new CRISPR-based diagnostic tool, MPXV-CRISPR, has been developed in Australia to detect the monkeypox virus with high precision and speed. The tool can detect the virus in clinical samples in just 45 minutes, making it faster than current methods.
Australian researchers analyzed over 1,300 Golden staph strains, linking specific genes to antibiotic resistance and the bacteria's ability to linger in the bloodstream. The study highlights the diagnostic power of integrating clinical and genomic data to develop targeted solutions for deadly superbug infections.
Research by the Peter Doherty Institute found that inflammation alters plasma composition, hindering parasite maturation. This work reveals a new mechanism slowing down malaria parasite development in the bloodstream.
University of Melbourne researchers have discovered that T cells patrol the human eye, protecting it from pathogens and inflammation. The study uses a new imaging technique to capture dynamic behavior of these cells in response to different stimuli.
A breakthrough mRNA vaccine has been developed to target and stimulate protective immune cell responses against malaria. The vaccine combines an RNA-based approach with a liver-specific adjuvant, generating resident memory cells that halt malaria infection in the liver, providing a broader and more protective immune response.
Research reveals that asymptomatic throat carriage of Streptococcus pyogenes is the primary source of Group A Streptococcus (GAS) infections in high-risk communities. This discovery challenges previous understanding of GAS transmission and has significant implications for public health approaches, vaccine development, and future research.
Researchers have discovered how Golden staph, a common bacterial infection, hides inside human cells to avoid detection. The study used InToxSa, a new methodology that enables the study of Golden staph behavior on a large scale.
A new study found that COVID-19 vaccination triggers effective immune responses against the virus in Aboriginal and Torres Strait Islander peoples. The research shows excellent antibody and T cell responses against SARS-CoV-2, with high levels of antibodies binding to the virus following two vaccine doses.
A breakthrough surveillance tool has been developed to detect elevated risks of Buruli ulcer outbreaks in Victoria, utilizing possum 'poo' analysis. The tool reveals significant spatial correlation between clusters of Mycobacterium ulcerans positive possum excreta and human Buruli ulcer cases.
A new study by the Peter Doherty Institute found that First Nations populations are significantly more likely to be hospitalized and die from influenza compared to non-Indigenous populations. Influenza-associated hospitalization and mortality rates were consistently higher in First Nations communities globally.
A study published in JCI Insight found that pregnant women display robust immune responses to SARS-CoV-2 infection, comparable to those of non-pregnant women. Key differences were observed in the dynamics of innate immune cells at the first line of defense towards viral infections.
Researchers found that COVID-19 vaccination generates robust T cell responses in haematology patients, on par with healthy individuals. The study provides key insights for future immunisation strategies and shows that mRNA vaccines can elicit strong T cell immunity in patients with co-morbidities.
An international study found that an intermediate level of anticoagulation had a high probability of being better than low dose anticoagulation, with no increased risk of bleeding. The study's findings inform WHO guidelines and provide evidence for a middle ground in COVID treatment.
Researchers have discovered the molecular mechanism that controls MR1, a protein responsible for alerting white blood cells to bacterial infections or cancer. By regulating MR1's activation, the immune response can be stimulated or inhibited, offering new potential for harnessing and controlling immunity.
A study found that unvaccinated children develop a rapid immune response to SARS-CoV-2, which may contribute to less severe symptoms, but limits the development of an immune memory response. Vaccination is believed to strengthen immunity by inducing key components such as memory T cell and B cell responses.
A groundbreaking study has discovered that the cornea produces a delicate immune response to fight viral infections without damaging vision. Long-living memory T cells have been found patrolling and fighting viral infections in the cornea, upending previous thought on T cell presence in healthy corneas.
Researchers found that vaccine-induced T cells remain stable for up to 15 months after vaccination or infection, recognizing the SARS-CoV-2 spike protein. This long-lasting immune response is crucial in supporting the development of antibodies against the virus.
Researchers have found that SARS-CoV-2 variants can emerge more quickly than expected, driven by a short-lived increase in mutation rate. This phenomenon was observed in variants such as Delta, which emerged within six weeks of its ancestral form.
A new standardised test has been developed to accurately determine the transmission of VREfm, enabling rapid identification of potential outbreaks and early intervention. The framework uses genomic analysis to compare bacterial genomes and infer transmission links, facilitating global deployment for outbreak detection and investigation.
Researchers found that cancer immunotherapy pembrolizumab can reverse HIV latency, allowing killer T cells to regain function and kill infected cells. The treatment, which blocks exhaustion markers, also perturbs the HIV reservoir, showing promise for a cure.